Ardelyx appoints Mark Kaufmann as chief business officer

Role includes business development, licensing and strategic planning

Ardelyx, a US developer of oral therapeutics to correct metabolic disorders, has appointed Mark Kaufmann to the newly created position of chief business officer. The role at the Fremont, CA company will include business and corporate development, licensing, and strategic planning.

Kaufmann was formerly chief executive of Allostera and Celmed BioSciences.

‘Mark’s deep understanding of the biotechnology business, coupled with his substantial experience at the most senior levels in business development and planning will serve Ardelyx well during our next phase of corporate development,’ said Mike Raab, chairman and ceo of Ardelyx.

Kaufmann has more than 20 years of experience in the biopharmaceutical industry in the US and Canada in business and corporate development roles.

Most recently, he was president and ceo of Allostera Pharma, a venture-backed, preclinical company focused on autoimmune diseases.

Prior to joining Allostera, Kaufmann was president and ceo of Celmed BioSciences, where he was responsible for raising funds and selling the company to Kiadis Pharma, a European biotechnology company. He has also held roles at Nexia Biotechnologies, Conceptis Technologies and MedImmune.

You may also like

Ingredients

Therapeutic: tenapanor for hyperphosphataemia

Patients with chronic kidney disease being treated with dialysis are at risk of developing hyperphosphataemia. This elevation of phosphorus levels is associated with cardiovascular morbidity and mortality
Marketing

Guardtech Group welcome new ‘cleanroom chameleon’ mascot into the mix to celebrate company’s role as enablers of change

Cammi the Chameleon will be appearing across the East Anglian cleanroom construction specialists’ marketing throughout 2026 to represent Guardtech’s aim to support groundbreaking developments in Life Sciences and beyond
Drug Delivery

SCHOTT Pharma and SHL Medical pre-validate polymer cartridge platform for large-volume autoinjectors

SCHOTT Pharma has pre-validated its ISO-standardised TOPPAC polymer cartridge for compatibility with SHL Medical’s large-volume Maggie autoinjector platform. The collaboration delivers a de-risked, ready-to-use solution for the safe at-home administration of large-volume therapies
Microbiology

Ingenza debuts Bacillus protein production system alternative to E. coli

The Scottish CRDMO's new GenXpress Bacillus technology offers a highly productive alternative to the traditional E. coli expression systems that is free from endotoxins and antibiotic resistance markers
Sustainability

BioDuro sites recognised with EcoVadis Gold and Silver sustainability certifications

Three of the CDMO's Chinese sites have been recognised for outstanding sustainability performance, highlighting BioDuro’s commitment to sustainability and its ongoing efforts to embed environmental and social responsibility into its business operations
Manufacturing

IMA Life-Sharp Sterile Manufacturing partnership strengthened with aseptic technology facility

Sharp's expanded facility in Massachusetts will include the installation of a fully automated IMA Life isolated filling line for Ready-To-Use (RTU) vials, addressing demand for US-based aseptic fill-finish services
Manufacturing

Cellistic launches three new iPSC-based GMP platforms to advance immuno-oncology and regenerative therapies

The three new iPSC-derived GMP manufacturing platforms, Echo-T, Echo-Cardio and Echo-Endothelial, expand the company’s Echo portfolio and are designed to improve scalability and manufacturability across immuno-oncology and regenerative medicine programmes
Subscribe now